Welcome to our dedicated page for Compugen news (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen stock.
Compugen Ltd. develops cancer immunotherapy programs using its AI/ML-powered Unigen computational discovery capabilities to identify drug targets and biological pathways. News about CGEN commonly covers clinical and preclinical immuno-oncology programs, including COM701, COM902, rilvegostomig and GS-0321, as well as updates tied to immune-checkpoint targets such as PVRIG, TIGIT and IL-18 binding protein.
Recurring company developments include quarterly and annual financial results, corporate updates, scientific conference presentations, clinical data disclosures, partnership activity with AstraZeneca and Gilead, royalty and license arrangements, and board or leadership changes. Compugen's ordinary shares trade on Nasdaq and the Tel Aviv Stock Exchange under the ticker CGEN.
Compugen Ltd. (CGEN) announced a $7.5 million milestone payment from AstraZeneca following the initiation of the ARTEMIDE Phase 2 study for AZD2936, a PD-1/TIGIT bispecific antibody. This advancement reinforces confidence in Compugen's COM902 antibody, which is part of their collaboration with AstraZeneca. To date, Compugen has received a total of $18.5 million in payments from AstraZeneca, part of a potential $200 million milestone agreement for the development of bispecific products. The company aims to leverage this opportunity while continuing its focus on its own pipeline of cancer immunotherapies.
Compugen Ltd. (CGEN) reported preliminary clinical data at SITC 2022 highlighting the effectiveness of COM701 combined with nivolumab in metastatic MSS-CRC patients, achieving a 12% response rate. The company plans further clinical trials, including a triple combination with anti-PD-1 and COM902. Additionally, promising data from ovarian cancer cohorts will be presented at ESMO-IO. As of September 30, 2022, Compugen maintains a solid balance sheet with $88 million in cash, expected to last through 2024, despite a net loss of $11.7 million for Q3 2022.
Compugen Ltd. (NASDAQ: CGEN), a clinical-stage cancer immunotherapy company, announced its participation in the Stifel 2022 Healthcare Conference on November 15, 2022, at 9:10 am ET. CEO Anat Cohen-Dayag and other management team members will engage in a fireside chat during the event in New York City. A live webcast will be available on Compugen's Investor Relations website, with a replay accessible afterward. The company focuses on innovative drug targets for cancer treatment, with proprietary candidates like COM701 and COM902.
Compugen Ltd. (CGEN) announced promising data on COM701, an anti-PVRIG antibody, demonstrating anti-tumor activity in MSS-CRC patients resistant to usual checkpoint inhibitors. The study highlights significant immune activation within the tumor microenvironment, suggesting COM701's potential to enhance T cell responses when combined with nivolumab. Notable findings include PVRIG's expression on early differentiated stem-like memory T cells, potentially inhibiting T cell expansion in tumors. The data will be elaborated upon during a Q3 earnings call on November 14, 2022, following an oral presentation at SITC on November 11, 2022.
Compugen Ltd. (NASDAQ: CGEN) announced promising preliminary data on its drug COM701 in combination with nivolumab for treating metastatic MSS-CRC patients. The study shows a 12% overall response rate in patients with liver metastases, a significant improvement over historical rates of 0% for similar therapies. Translational data reveal strong immune activation in the tumor microenvironment, indicating a potential breakthrough for this typically non-responsive cancer. The company plans further clinical evaluations and will present detailed findings at the SITC meeting on November 10, 2022.
Compugen Ltd. (NASDAQ: CGEN) received a notification from Nasdaq on October 31, 2022, stating that its ordinary shares failed to maintain the minimum bid price of $1.00 for 30 consecutive business days, as required by Nasdaq Listing Rule 5450(a)(1). The company has a compliance period of 180 days, until May 1, 2023, to regain compliance. If the bid reaches $1.00 for 10 consecutive days before this date, compliance will be confirmed. Failure to comply may lead to delisting, but the company can appeal and possibly receive an additional grace period.
Compugen Ltd. (Nasdaq: CGEN) announced it will release its third quarter 2022 financial results on November 14, 2022, before U.S. market opening. Management will host a conference call at 8:30 AM ET to discuss the results and provide a corporate update, including data to be presented at the Society for Immunotherapy of Cancer meeting from November 8-12, 2022. Compugen focuses on cancer immunotherapy, developing products like COM701 and COM902, and has partnered with Bayer and AstraZeneca on other programs.
Compugen Ltd. (Nasdaq: CGEN) announced new clinical data presentations for COM701 and its combinations at the ESMO-IO congress from December 7-9, 2022, in Geneva. Key presentations include findings on the triple blockade of the DNAM-axis in platinum-resistant ovarian cancer, and COM701's use in metastatic NSCLC patients previously treated with PD-1/PD-L1 inhibitors. These results aim to highlight the antitumor activity of Compugen's therapeutic candidates, advancing their immuno-oncology pipeline.
Compugen Ltd. (Nasdaq: CGEN) announced its participation in the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on November 10-12, 2022, in Boston, MA. The company will present new clinical data from the COM701/nivolumab cohort expansion study for metastatic MSS-CRC, highlighting preliminary antitumor activity. Additionally, research on PVRIG, a novel T cell checkpoint, will be presented. Presentation details include two oral sessions on November 10 and 11, featuring abstract numbers 659 and 504, respectively. More information will be available on Compugen's website post-event.
Compugen Ltd. (CGEN) provided an update to shareholders on September 22, 2022, highlighting strong fundamentals despite market challenges. The company is prioritizing indications with the highest chance of success and has sufficient cash flow to operate into 2024. Data shows promising anti-tumor activity for COM701 in ovarian cancer and upcoming data for COM701/nivolumab in MSS-CRC by Q4 2022. Compugen announced a strategic focus on triple combinations in its pipeline, including COM701 and COM902, while maintaining a solid balance sheet with no debt.